E2F1-dependent oncogenic addiction of melanoma cells to MDM2 (original) (raw)

• Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK . (2007). Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26: 3473–3481.
  Article CAS Google Scholar
• Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP et al. (2008). Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 14: 1659–1668.
  Article CAS Google Scholar
• Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L . (2001). Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 21: 2144–2153.
  Article CAS Google Scholar
• Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864–870.
  Article CAS Google Scholar
• Bennett DC . (2008). How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 21: 27–38.
  Article CAS Google Scholar
• Campanero MR, Flemington EK . (1997). Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc Natl Acad Sci USA 94: 2221–2226.
  Article CAS Google Scholar
• Castresana JS, Rubio MP, Vazquez JJ, Idoate M, Sober AJ, Seizinger BR et al. (1993). Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 55: 562–565.
  Article CAS Google Scholar
• Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR et al. (2006). Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 8: 1053–1063.
  Article CAS Google Scholar
• Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari Jr AW et al. (2005). Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65: 6294–6304.
  Article CAS Google Scholar
• Fu W, Ma Q, Chen L, Li P, Zhang M, Ramamoorthy S et al. (2009). MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem 284: 13987–14000.
  Article CAS Google Scholar
• Gray-Schopfer V, Wellbrock C, Marais R . (2007). Melanoma biology and new targeted therapy. Nature 445: 851–857.
  Article CAS Google Scholar
• Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE et al. (2007). ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA 104: 10968–10973.
  Article CAS Google Scholar
• Hoek KS . (2007). DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 20: 466–484.
  Article CAS Google Scholar
• Hofmann F, Martelli F, Livingston DM, Wang Z . (1996). The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev 10: 2949–2959.
  Article CAS Google Scholar
• Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J . (2006). MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 281: 33030–33035.
  Article CAS Google Scholar
• Huang B, Deo D, Xia M, Vassilev LT . (2009). Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol Cancer Res 7: 1497–1509.
  Article CAS Google Scholar
• Jemal A, Siegel R, Xu J, Ward E . (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
  Article Google Scholar
• Kass EM, Poyurovsky MV, Zhu Y, Prives C . (2009). Mdm2 and PCAF increase Chk2 ubiquitination and degradation independently of their intrinsic E3 ligase activities. Cell Cycle 8: 430–437.
  Article CAS Google Scholar
• Korotchkina LG, Demidenko ZN, Gudkov AV, Blagosklonny MV . (2009). Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle 8: 3777–3781.
  Article CAS Google Scholar
• Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E et al. (2008). Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68: 3193–3203.
  Article CAS Google Scholar
• Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H et al. (2010). Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 116: 71–80.
  Article CAS Google Scholar
• Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720–724.
  Article CAS Google Scholar
• Moran DM, Maki CG . (2010). Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther 9: 895–905.
  Article CAS Google Scholar
• Murga M, Bunting S, Montana MF, Soria R, Mulero F, Canamero M et al. (2009). A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet 41: 891–898.
  Article CAS Google Scholar
• Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y et al. (2007). Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 104: 19488–19493.
  Article CAS Google Scholar
• Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15: 249–254.
  Article CAS Google Scholar
• Polager S, Ginsberg D . (2009). p53 and E2f: partners in life and death. Nat Rev Cancer 9: 738–748.
  Article CAS Google Scholar
• Polsky D, Cordon-Cardo C . (2003). Oncogenes in melanoma. Oncogene 22: 3087–3091.
  Article CAS Google Scholar
• Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW . (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934–2949.
  Article CAS Google Scholar
• Prieur A, Peeper DS . (2008). Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 20: 150–155.
  Article CAS Google Scholar
• Ryan KM, Phillips AC, Vousden KH . (2001). Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332–337.
  Article CAS Google Scholar
• Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M et al. (2000). Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 11: 467–474.
  CAS PubMed Google Scholar
• Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R et al. (2005). MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20: 699–708.
  Article CAS Google Scholar
• Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S et al. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105: 3933–3938.
  Article CAS Google Scholar
• Shangary S, Wang S . (2009). Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223–241.
  Article CAS Google Scholar
• Shen H, Moran DM, Maki CG . (2008). Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res 68: 8260–8268.
  Article CAS Google Scholar
• Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS et al. (2007). An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 67: 209–217.
  Article CAS Google Scholar
• Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. (2001). Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207–211.
  Article CAS Google Scholar
• Soengas MS, Lowe SW . (2003). Apoptosis and melanoma chemoresistance. Oncogene 22: 3138–3151.
  Article CAS Google Scholar
• Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA et al. (2010). p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res 23: 781–794.
  Article CAS Google Scholar
• Vassilev LT . (2007). MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23–31.
  Article CAS Google Scholar
• Vazquez A, Bond EE, Levine AJ, Bond GL . (2008). The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979–987.
  Article CAS Google Scholar
• Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC et al. (2006). A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66: 11348–11359.
  Article CAS Google Scholar
• Verma R, Rigatti MJ, Belinsky GS, Godman CA, Giardina C . (2010). DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 79: 565–574.
  Article CAS Google Scholar
• Vousden KH, Prives C . (2009). Blinded by the light: the growing complexity of p53. Cell 137: 413–431.
  Article CAS Google Scholar
• Wade M, Wang YV, Wahl GM . (2010). The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20: 299–309.
  Article CAS Google Scholar
• Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR et al. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694–698.
  Article CAS Google Scholar
• Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H . (2006). Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol 126: 2490–2506.
  Article CAS Google Scholar
• Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R . (2004). MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 279: 16000–16006.
  Article CAS Google Scholar
• Zhu Y, Poyurovsky MV, Li Y, Biderman L, Stahl J, Jacq X et al. (2009). Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell 35: 316–326.
  Article CAS Google Scholar